Skip to main content

Arbuckle Stuart A's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Feb 14, 2023

Accession no.
0001209191-23-009182
Filed
Feb 14, 2023
Trade date
Feb 10-13, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions. Open-market sales total $1.46M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Arbuckle Stuart ACIK 0001557290Officer (EVP, COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 10, 2023Common StockFTax withholdingDisposed−3,372$294.33−$992,480.7692,880Direct
Feb 13, 2023Common StockFTax withholdingDisposed−5,990$298.26−$1,786,577.486,890Direct
Feb 13, 2023Common StockSSaleDisposed−245$296.44F2,F3−$72,627.886,645Direct
Feb 13, 2023Common StockSSaleDisposed−2,028$298.42F2,F4−$605,195.7684,617Direct
Feb 13, 2023Common StockSSaleDisposed−1,779$299.26F2,F5−$532,383.5482,838Direct
Feb 13, 2023Common StockSSaleDisposed−835$300.13F2,F6−$250,608.5582,003Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 4 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $298.42 (range $297.85 to $298.80).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $299.26 (range $298.86 to $299.81).

Referenced by the price of 1 transaction in Table I.

F6

Open market sales reported on this line occurred at a weighted average price of $300.13 (range $299.93 to $300.53).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)